Skip to content

Advertisement

  • Oral presentation
  • Open Access

Review of the interactions between G6PD deficiency and primaquine therapy for malaria control and elimination

  • 1
Malaria Journal201413 (Suppl 1) :O11

https://doi.org/10.1186/1475-2875-13-S1-O11

  • Published:

Keywords

  • Malaria
  • Plasmodium
  • Plasmodium Falciparum
  • Malaria Control
  • G6PD Deficiency

Primaquine is an essential drug for malaria control and elimination by being the only drug active against the liver-reservoir of Plasmodium vivax infections and also the only drug against the mature sexual stages of Plasmodium falciparum which are responsible for onward transmission to mosquitoes. Nevertheless, uncertainty associated with this drug’s safety results in under-use due to difficulties with diagnosing glucose-6-phosphate dehydrogenase deficiency (G6PDd) in point-of-care settings. This common genetic disorder makes patients susceptible to potentially severe, and occasionally even fatal, primaquine-induced haemolysis.

Policy shifts towards malaria elimination in recent years have led to a surge of clinical trials and reviews of historical data to promote safe primaquine use. This talk will examine evidence of the drug’s use and outcomes in geographic regions with distinct epidemiological characteristics. For each setting, the parasite epidemiology, the population’s G6PDd characteristics, and the current primaquine policies will be discussed. The quality and completeness of the parasitological, G6PDd and clinical evidence-bases that inform primaquine policy is examined; the importance of context-specific evaluations of primaquine use is emphasized.

Authors’ Affiliations

(1)
University of Oxford, UK

Copyright

© Howes; licensee BioMed Central Ltd. 2014

This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.

Comments

By submitting a comment you agree to abide by our Terms and Community Guidelines. If you find something abusive or that does not comply with our terms or guidelines please flag it as inappropriate. Please note that comments may be removed without notice if they are flagged by another user or do not comply with our community guidelines.

Advertisement